Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access

BioSpace | March 20, 2020

Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Microsoft Corp. (Nasdaq: MSFT) on Friday announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease, augmenting existing research efforts that primarily focus on the biology of the virus. These data will be made freely available to any researcher, public health official or organization around the world via an open data access portal.

Spotlight

Throughout the process, magnets are utilized to isolate the DNA, making the protocol simple and scalable. Eight samples can be processed manually, or 24 samples can be processed when using the KingFisher™ Flex Magnetic Particle Processor with 24 Deep-Well Head.


Other News
INDUSTRIAL IMPACT

Lummus and Synthos Advance Bio-Butadiene Technology Development to Produce Sustainable Rubber

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for renewable materials, Synthos has committed to building a plant with a capacity of 40,000 metric tons of bio-butadiene per year – twice as much as the companies had originally planned. In addition to the plant capacity expansion, Synthos has confirmed that it will license BASF's butadiene extraction technology from Lummus and leverage Lummus' digitalization capabilities for operational efficiency and reliability. "Since Lummus began collaborating with Synthos last year, it has become evident that this technology has the potential to be the new standard in our industry due to its renewable sourcing, production efficiency and low carbon footprint. The petrochemical industry is quickly adjusting to ambitious sustainability requirements, and at Lummus we continue to lead this change on multiple fronts. The commercialization with Synthos of this bio-technology for more sustainable rubber products is one of several sustainable process solutions that are making a positive impact." Leon de Bruyn, President and Chief Executive Officer of Lummus Technology "Synthos is making great strides in developing a synthetic rubber product portfolio with a significantly reduced environmental footprint. Entering the next phase of our collaboration with Lummus is another step toward our commitment to help our customers achieve their performance and sustainability goals," said Matteo Marchisio, Synthetic Rubber Business Unit Director, Synthos. "We believe the availability of sustainable synthetic rubber made from bio-butadiene will play an important role in the industry's ability to meet the demands of modern mobility, and we are proud to partner with Lummus Technology to lead the way." Synthos is a global leader in the development and production of synthetic rubber for tires and technical rubber goods and is committed to providing its customers with high-performance material solutions with a lower environmental footprint. In 2021, Green Circle and Synthos announced that they will collaborate on the development and commercialization of bio-butadiene derived from bio-ethanol to enable the production of value-added, more sustainable synthetic rubber. A subsidiary of Lummus, Green Circle is a leader in commercializing and developing breakthrough solutions to address the key pillars of the energy transition, including end-of-life waste plastics recycling, production of bio derived sustainable chemicals, and decarbonization strategies for existing and new assets. About Lummus Technology Lummus Technology is the global leader in developing process technologies that make modern life possible and focus on a more sustainable, low carbon future. Lummus is a master licensor of clean energy, petrochemical, refining, gas processing and renewable technologies, and a supplier of catalysts, proprietary equipment, digitalization and related lifecycle services to customers worldwide. About Synthos Synthos S.A. is a chemical producer and a major player in the global synthetic rubber market. Synthos S.A. Capital Group's business includes the production and sales of chemical products used as raw materials and intermediates in a wide range of industries, particularly in the tire industry, the construction industry and the packaging industry.

Read More

MEDICAL

Light Bio Partners with Ginkgo Bioworks to Optimize the Brightness of Glowing Plants through Bioluminescence Engineering

Light Bio | April 18, 2022

Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new type of bioluminescence mechanism and are using synthetic biology to engineer plants to efficiently emit light. The original light emission pathway Light Bio uses in its glowing plants comes from bioluminescent mushrooms, and the company is now focused on expanding its engineering capabilities to support the creation of glowing plants. We are excited to collaborate with Ginkgo toward additional multifold output and efficiency improvements powered by Ginkgo's plant cell engineering capabilities across both individual enzyme and metabolic pathway improvements, Light Bio has already achieved strong light emission results on our glowing plant luminescence to date." Keith Wood, CEO, Light Bio. Nothing captures the wonder of biology quite like seeing glowing plants in person, Our platform enables developers to imagine with biology and to design all types of cells, from bacteria and yeast to mammalian and plant cells. We're so excited to bring this unique application onto our platform and to help Light Bio bring the magic of glowing plants to people." Jason Kelly, CEO, Ginkgo Bioworks. About Light Bio Light Bio creates novel biodesigns in living light. Through consumer-led applications of synthetic biology, Light Bio is opening new markets with products that have never existed before. Led by a team with deep experience in the development and commercialization of bioluminescence products, the company is sustained by its proprietary technologies backed by a strong patent portfolio. About Ginkgo Bioworks Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery.

Read More

CELL AND GENE THERAPY

Gracell Biotechnologies Unveils Innovation Center in U.S.

Gracell Biotechnologies Inc | January 13, 2022

Gracell Biotechnologies Inc. a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022. As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and diversify its in-house drug discovery, pre-clinical research, and translational capabilities to further complement its proprietary platforms and extensive early-stage pipeline. After a thorough nationwide search, Gracell chose to establish its Innovation Center within the Cornerstone Research Center in San Diego. The new hub includes a state-of-the-art laboratory, along with office space. Gracell is also expanding its R&D team through the recruitment of high-caliber biotech talent in the San Diego area. "We are delighted to start 2022 with the opening of our U.S. Innovation Center in San Diego, which will strengthen our R&D capabilities and further expand our presence in the U.S. market. This marks another solid step in Gracell's journey of becoming a leading global cell therapy company. By innovating and expanding upon our proprietary FasTCAR and TruUCAR platforms, we remain focused on solving the challenges of conventional CAR-T cell therapies and advancing innovative, highly differentiated programs from our robust pipeline to benefit cancer patients all around the world." Dr. William (Wei) Cao, Founder, Chairman and Chief Executive Officer of Gracell About Gracell Gracell Biotechnologies Inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CARTTM technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.

Read More

INDUSTRIAL IMPACT

c-LEcta Announces That It Has Reached Agreement to Be Acquired by Kerry Group

c-LEcta | February 16, 2022

c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-LEcta to fufill its long term growth potential. “We are very happy to join Kerry group and their global presence in the food and pharmaceutical sectors gives us access to additional markets. At the same time, their expertise in ingredient technologies and applications is a perfect fit as we continue to drive our growth potential in the future. We will continue to collaborate with our existing industry partners and will of course continue to produce and distribute our products for our valued customers.” Dr Marc Struhalla, founder and CEO of c-LEcta Thomas Pfaadt, CFO of c-LEcta adds: “We want to thank our previous investors for the great cooperation over the past years. Without their contribution, such a development would not have been possible. Together, we have achieved a lot and we are thankful for their support.” Commenting on the agreement with c-LEcta, Dr Albert McQuaid, Chief Science and Technology Officer of Kerry, said: “The food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors. c-LEcta is a leader in these new technologies, which includes fermentation-based products such as disruptive new enzymes, and the strategically compelling combination with Kerry will accelerate our innovation capabilities in enzyme engineering, fermentation and bio-process development. Our broad market reach across food and pharma markets, combined with our deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta’s strong portfolio and technology capabilities while also supporting us in the creation of tastier, more sustainable and healthier products.” About c-LEcta c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets. About the Kerry Group Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets and with its broad portfolio of ingredient solutions reaches more than one billion customers worldwide. Together with their customers, Kerry develops innovative products with great taste, improved nutritional value, and higher functionality, while having a better impact on the environment. Thanks to their leading consumer knowledge, their global RD&A team with more than 1,100 food scientists, and their comprehensive, global presence, Kerry can overcome the complex challenges of their customers with differentiated solutions. Kerry is willing to be a valued partner for their customers and to create a world of sustainable nutrition.

Read More